Health
FDA approves HYMPAVZI for hemophilia patients
FDA approves HYMPAVZI for two additional hemophilia A or B patient populations, addressing significant unmet medical nee…
Marcus Rivera·
9 articles
FDA approves HYMPAVZI for two additional hemophilia A or B patient populations, addressing significant unmet medical nee…
FDA-approved oral AML therapy allows older patients to avoid monthly infusion visits, marking a significant advance in p…
FDA approves new prostate cancer companion diagnostics, FoundationOne CDx and Liquid CDx, for targeted mCRPC therapy.
FDA approves the first gene therapy for genetic hearing loss on May 9, 2026, marking a significant advance in treating i…
US FDA approves Pfizer, Arvinas’ breast cancer drug on May 2, 2026, offering new hope and a significant advancement in o…
CSPC Pharmaceutical’s SYH2059 KAT6 inhibitor receives FDA approval for clinical trials in the U.S., marking a significan…
Merck’s novel combo pill Idvynso receives FDA approval, amplifying its presence in the HIV treatment market and offering…
Pfizer is seeking FDA approval for a new Lyme disease vaccine, a landmark development that could transform public health…
A landmark FDA drug approval for a rare disease offers hope to an Overland Park family, highlighting a growing trend in…